End Cash: The amount of cash held by the company for the given period.
Larimar Therapeutics, Inc. (LRMR) had End Cash of $86.02M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-165.67M |
|
-- |
|
-- |
|
$172.50M |
|
$-172.50M |
|
$6.82M |
|
$-165.67M |
|
$-165.67M |
|
$-165.67M |
|
$-165.67M |
|
$-165.67M |
|
$-165.67M |
|
$-172.50M |
|
$-173.84M |
|
72.95M |
|
72.95M |
|
$-2.27 |
|
$-2.27 |
|
| Balance Sheet Financials | |
$142.02M |
|
$0.62M |
|
$3.82M |
|
$145.84M |
|
$64.80M |
|
-- |
|
$2.96M |
|
$67.76M |
|
$78.08M |
|
$78.08M |
|
$78.08M |
|
83.09M |
|
| Cash Flow Statement Financials | |
$-113.20M |
|
$100.31M |
|
$65.09M |
|
$33.82M |
|
|
End Cash |
$86.02M |
$52.19M |
|
$7.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-113.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-212.17% |
|
-212.17% |
|
-113.60% |
|
-212.17% |
|
$0.94 |
|
$-1.55 |
|
$-1.55 |
|